Medindia

X

GENEWIZ Expands High Throughput Sequencing Capabilities with Investment in Multiple Platforms

Saturday, April 16, 2016 General News J E 4
Advertisement
HiSeq X Ten, PacBio Sequel, and 10x Genomics Added to Line-up

SOUTH PLAINFIELD, N.J. and NEW ORLEANS, April 15, 2016 /PRNewswire/ -- (AACR16, Booth #2241) -- GENEWIZ, a leading global genomics services provider, announced today it has acquired multiple high-throughput sequencing (also known as Next Generation Sequencing (NGS)) platforms including the Illumina HiSeq X Ten, PacBio Sequel, and 10x Genomics Chromium. The addition of these cutting-edge systems strengthens the scope of the NGS services GENEWIZ offers the scientific community worldwide.

Photo - http://photos.prnewswire.com/prnh/20160415/355967LOGO

"Our purchase of the X Ten, the sequencing system with the highest throughput, allows our customers access to an unprecedented scale of whole genome sequencing (WGS) for species of all types including human, animal, plant and beyond," said Dr. Steve Sun, GENEWIZ CEO. "Additionally, the PacBio Sequel for long-read, single molecules and the 10x Genomics system for single cell sequencing will make GENEWIZ a complete solution provider for all NGS projects."

These new platforms complement GENEWIZ's existing HiSeq, MiSeq, and Ion Torrent platforms providing a variety of sequencing read lengths and throughput options to accommodate all kinds of research and application needs for different project costs and timelines. The strength of these diverse platform capabilities combined with GENEWIZ's powerful bioinformatics services will allow research scientists worldwide to efficiently advance their discoveries.

"After the successful acquisition of Beckman Coulter Genomics business, this investment in these new powerful machines reinforces GENEWIZ's position as a global leader in genomics services. Our customers will continue to enjoy the most advanced technology, highest quality and unsurpassed services provided by our dedicated team," added Dr. Sun.

Researchers can discuss upcoming projects with GENEWIZ technical specialists during the American Association for Cancer Research (AACR) Annual Meeting (Booth #2241), which takes place April 16-20 in New Orleans, USA.

GENEWIZ's certified high-throughput platforms, proprietary services, expansive bioinformatics capabilities, combined with its team of industry experts and Ph.D.-level specialists, deliver accurate data for timely downstream advancements. NGS service offerings include, but not limited to: RNA-Seq, Whole Genome Sequencing, Targeted Resequencing, Amplicon Sequencing, Metagenomics, and Cancer Panels. For additional information, visit www.genewiz.com or contact the Project Management team at PM@genewiz.com or by calling 877-GENEWIZ (US) / +1-908-222-0711 (Outside US), ext. 3.

About GENEWIZGENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Suzhou, China; Beijing, China; Tianjin, China; London, United Kingdom; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, Weibo, and WeChat.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genewiz-expands-high-throughput-sequencing-capabilities-with-investment-in-multiple-platforms-300252330.html

SOURCE GENEWIZ

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
2023 Multiple Myeloma Market Analysis, Trends and ...
S
New Initiative to Consult with Veterans Stakeholde...